![]() Fusion stops motion at the treated level and ultimately reduces back pain originating from the degenerated disc. Two of the rhBMP-2 loaded cages are implanted into an intervertebral spinal disc space to promote bone growth across the disc, i.e., spinal fusion. After a minimum of 15 minutes to allow binding, the collagen sponge is rolled up and placed into a titanium spinal fusion cage. ![]() The protein is applied to a type I collagen sponge at the time of surgery. It was cleared as a combination biologic device after petitioning the FDA in the early 1990s with the argument that rhBMP-2's effects were only local and not systemic. Its commercial trade name is INFUSE Bone Graft. Local delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2) as a bone graft substitute in spinal fusion was Food and Drug Administration approved on July 2, 2002. ![]()
0 Comments
Leave a Reply. |